Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders

摘要

This invention relates to the use of the NK3 receptor antagonist talnetant [(S)-(-)-N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide] for treating bipolar disorder.